Corporate Advisory Board
Lee, Dongho, MD, Ph.D
Dr.Lee is a co-founder of BioDesigners. He was the first CEO of the Korea Drug Development Fund and before then, he worked as a professor at the University of Ulsan College of Medicine and a head of the Clinical Research Center at the Asan Medical Center. He also served as a vice president at Samyang Corporation and GlaxoSmithKline Korea, respectively.
Dr. Lee obtained BS, MS, MD and Ph.D from Seoul National University and MBA from Korea University.
Lee, James Jungkue
Mr. Lee co-founded Bridge Biotherapeutics in 2015, and serves as CEO. He is also serving multiple Korean biotech companies as BD advisor. Prior to Bridge, he founded Rexbio, specialized in discovery of monoclonal antibody for the treatment of pancreatic cancer. He co-founded CrystalGenomics in 2000 and had played key roles in financing and business development until 2007.
He started industry career at LG Chemical Ltd (currently LG Life Sciences) in 1993 after earning MS degree at Department of Chemistry, Seoul National University.
Lee, Sung-Joo, Ph.D
Dr. Lee is the founder of Orum Therapeutics. Recently, he was the head of research, Asia Pacific R&D at Sanofi. Previously, he worked as a general manager at LG Life Science.
Dr. Lee earned BS from Yonsei University and Ph.D from University of California, Berkeley.
Kim, Jason Jaesoon
Mr. Kim is the CEO of J&R Partners. Prior to J&R Partners, Mr. Kim was a managing director of the Development Division at Daewoong Pharmaceutical. Before joining Daewoong Pharmaceutical, he held various positions in strategy and global business development at Hanmi Pharmaceutical and CJ Corporation. He also served as an equity analyst in biopharmaceutical sector at Mirae Asset Securities. Mr. Kim began his career at LG Chemical as a researcher and R&D planning manager of Pharmaceutical Division.
Mr. Kim received his BS and MS degree from Seoul National University.